Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8 + T lymphocytes, NK ‐cells, and high frequency of CD73 + stromal cells
Cancer Reports · 2023
DOI: 10.1002/cnr2.1817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2023. Verfasst von Pélagie Mougola Bissiengou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Immunologie, Département des Sciences Fondamentales, Faculté de Médecine, Université des Sciences de la Santé, Libreville, Gabon. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anti‐cancerous immunology has yet to be investigated in the African black population, despite being the dawn of precision medicine.
Aim
Here we investigated the tumor microenvironment of prostate cancer and benign prostatic hyperplasia (BPH) in black Africans.
Methods
Through immunohistochemistry analysis of prostate cancer and BPH patients' biopsies, we investigated the expression and distribution of CD73, CCD8 T‐lymphocytes, and natural killer cells. In addition, we looked at tumor‐infiltrating features CD8 T‐lymphocytes and natural killer cells.
Results
We show for the first time in black Africans a high expression of CD73 in epithelial‐stromal cells and virtually no infiltration of CD8 T lymphocytes and natural killer cells in the tumoral area. In addition, CD73 was seven (7) times more likely to be expressed in prostate cancer stromal tissues than in benign prostatic hyperplasia tissues (odds ratio = 7.2; χ 2 = 21; p < .0001). In addition, PSA concentration was significantly higher in prostate cancer patients than in BPH patients ( p < .001). Also, the PSA‐based ROC. analysis showed an area under the curve of 0.87 ( p < .0001).
Conclusion
CD73 expression is more likely expressed in prostate cancer stromal tissues than in benign prostatic hyperplasia tissues. The features of prostate cancer in Black Africans suggest CD73 expression as a possible target for immunotherapy in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Immunologie, Département des Sciences Fondamentales, Faculté de Médecine, Université des Sciences de la Santé, Libreville, Gabon.
- Service d'Immunologie, Département des Sciences Biologiques et Pharmaceutiques Appliquées, Faculté de Médecine, de Pharmacie et d'Odontostomatologie, Université Cheikh Anta Diop, Dakar, Senegal.
- Unité d'anatomie-Cytologie-Pathologie, Centre Hospitalier Universitaire de Libreville, Libreville, Gabon.
- Service Laboratoire, Centre Hospitalier Universitaire Mère-Enfant Fondation Jeanne EBORI, Libreville, Gabon.
ORCID-Profile: Joel Fleury Djoba Siawaya
Zitieren
APA
Mougola Bissiengou, P., Montcho Comlan, J. G., Atsame Ebang, G., Sylla Niang, M., & Djoba Siawaya, J. F. (2023). Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8 + T lymphocytes, NK ‐cells, and high frequency of CD73 + stromal cells. Cancer Reports. https://doi.org/10.1002/cnr2.1817
Vancouver
Mougola Bissiengou P, Montcho Comlan JG, Atsame Ebang G, Sylla Niang M, Djoba Siawaya JF. Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8 + T lymphocytes, NK ‐cells, and high frequency of CD73 + stromal cells. Cancer Reports. 2023. doi:10.1002/cnr2.1817
BibTeX
@article{MougolaBissiengou2023,
author = {Mougola Bissiengou, Pélagie and Montcho Comlan, Jérôme Gaston and Atsame Ebang, Gabrielle and Sylla Niang, Maguette and Djoba Siawaya, Joel Fleury},
title = {Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8 + T lymphocytes, NK ‐cells, and high frequency of CD73 + stromal cells},
journal = {Cancer Reports},
year = {2023},
doi = {10.1002/cnr2.1817}
}
EUVIMED